Discussion
Alentis Therapeutics and CSL are joining forces to develop and commercialize lixudebart, an infusion treatment candidate for people with ANCA-associated vasculitis (AAV) who also have rapidly progressive glomerulonephritis (RPGN), a severe form of kidney damage. The partnership joins Alentis‘ expertise as lixudebart’s original developer with CSL‘s…